Press Release: Waterloo Study Seeking Newly Diagnosed Diabetes Patients

A new diabetes study in the Kitchener-Waterloo area is investigating the effectiveness of a combination drug therapy of Metformin and Tradjenta (linagliptin) for people newly diagnosed with type 2 diabetes.

WireService.ca Press Release – May 10, 2012 – Kitchener, Ontario: A phase IV post-marketing research study in the Kitchener-Waterloo area is investigating the effectiveness of a combination drug therapy of Metformin and Tradjenta (linagliptin) for people newly diagnosed with type 2 diabetes. Metformin is often considered the first line of treatment against diabetes, and Tradjenta is a new anti-diabetic therapy that was approved by Health Canada in October of 2011.

To be considered eligible for the study, potential participants must:

Be Male or Female over 18 years of age
Be newly diagnosed with Type 2 Diabetes within the past 12 months
Have never used any anti-diabetic medications

An estimated 1 million Canadians have diabetes and don’t know it.1*

Type 2 diabetes is a disease in which a hormone known as insulin can no longer move sugars, or glucose, from the blood into cells. As a result, cells do not receive this vital energy source and starve.

Some signs of type 2 diabetes include frequent thirst and urination; tingling or numbness in the hands and feet; unintended weight loss; and slow healing cuts or sores. Since humans are unable to sense high blood glucose levels, and signs of type 2 diabetes may take years to develop, an estimated 1 million Canadians go years without a diagnosis. Long term elevated blood glucose levels contribute to a variety of complications such as blindness, kidney disease, amputations, hardening of the blood vessels and heart disease.

Some risk factors for developing diabetes include increasing age; a family history of the disease; being overweight or obese; heart disease or high blood pressure; infrequent doctor visits; and South Asian or African ethnicity. Finding more aggressive diabetes management options is essential and would help reduce the risk of serious complications.

About the Company

The Canadian Centre for Clinical Trials is a Toronto based company with the aim of engaging patients and physicians in clinical research. More information about the Canadian Centre for Clinical Trials can be found at:
http://www.clinicaltrialscanada.com.

For more information about the study please email info@clinicaltrialscanada.com, call 1-855-85-TRIAL (87425) or visit http://diabetes.clinicaltrialscanada.com

Call us to learn more about the study!

Company Contact:
Gazal Vakili
Clinical Research Manager
Gazal.Vakili@clinicaltrialscanada.com
Telephone: (289)-597-0106 ext. 112
Fax: (905)-886-1648

Source:

1 Canadian Diabetes Association: Get Checked Now http://www.getcheckednow.ca/

Leave a Reply

Your email address will not be published. Required fields are marked *